TNF and B-cell chronic lymphocytic leukemia: Moreover, Idelalisib antagonizes the microenvironmental triggers TNF-α, CD40L, BAFF, and fibronectin, all of which act by increasing AKT phosphorylation in CLL cells and protecting them from spontaneous apoptosis [4, 17, 29].